188 related articles for article (PubMed ID: 33324394)
1. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
Tseng JC; Wei JC; Deodhar A; Martin R; Porter B; McCreddin S; Talloczy Z
Front Immunol; 2020; 11():561748. PubMed ID: 33324394
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Baeten D; Baraliakos X; Braun J; Sieper J; Emery P; van der Heijde D; McInnes I; van Laar JM; Landewé R; Wordsworth P; Wollenhaupt J; Kellner H; Paramarta J; Wei J; Brachat A; Bek S; Laurent D; Li Y; Wang YA; Bertolino AP; Gsteiger S; Wright AM; Hueber W
Lancet; 2013 Nov; 382(9906):1705-13. PubMed ID: 24035250
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos X; Kivitz AJ; Deodhar AA; Braun J; Wei JC; Delicha EM; Talloczy Z; Porter B;
Clin Exp Rheumatol; 2018; 36(1):50-55. PubMed ID: 28516874
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
Kishimoto M; Taniguchi A; Fujishige A; Kaneko S; Haemmerle S; Porter BO; Kobayashi S
Mod Rheumatol; 2020 Jan; 30(1):132-140. PubMed ID: 30334633
[No Abstract] [Full Text] [Related]
10. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Baeten D; Sieper J; Emery P; Readie A; Martin R; Mpofu S; Richards HB;
Ann Rheum Dis; 2017 Jun; 76(6):1070-1077. PubMed ID: 27965257
[TBL] [Abstract][Full Text] [Related]
11. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S
Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Huang F; Sun F; Wan WG; Wu LJ; Dong LL; Zhang X; Kim TH; Sengupta R; Šenolt L; Wang Y; Qiu HM; Porter B; Haemmerle S
Chin Med J (Engl); 2020 Nov; 133(21):2521-2531. PubMed ID: 32925287
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Martin R; Readie A; Richards HB; Porter B;
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1020-1029. PubMed ID: 28235249
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
Kivitz AJ; Wagner U; Dokoupilova E; Supronik J; Martin R; Talloczy Z; Richards HB; Porter B
Rheumatol Ther; 2018 Dec; 5(2):447-462. PubMed ID: 30121827
[TBL] [Abstract][Full Text] [Related]
15. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis.
Lee YH; Song GG
Z Rheumatol; 2021 Oct; 80(8):776-784. PubMed ID: 32648054
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
Baraliakos X; Borah B; Braun J; Baeten D; Laurent D; Sieper J; Emery P; McInnes IB; van Laar JM; Wordsworth P; Wollenhaupt J; Kellner H; Colin L; Vandenhende F; Radford K; Hueber W
Ann Rheum Dis; 2016 Feb; 75(2):408-12. PubMed ID: 26248638
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
